SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

• Status: Completed
• Trial end date: 2016-09-01

Summary

Primary Objective:

Participants achieving an Objective Response Rate

Secondary Objective:

• Progression Free Survival

• Overall Survival

• Response Duration

• Safety

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Maytansine